On the Record

"I think these [FDA] guidances are important because they provide manufacturers more assurances about what information they can provide [and] lets them discuss the value of the product with payers."

— Tom Kraus, senior vice president at Avalere Health who leads the consulting firm’s life science commercialization practice, tells Radar on Drug Benefits about the FDA guidances on health care economic information